<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="335353">
  <stage>Registered</stage>
  <submitdate>20/04/2010</submitdate>
  <approvaldate>18/05/2010</approvaldate>
  <actrnumber>ACTRN12610000400066</actrnumber>
  <trial_identification>
    <studytitle>A Study to Evaluate the Safety and Efficacy of CCX140-B in Subjects with Type 2 Diabetes Mellitus</studytitle>
    <scientifictitle>A Randomized, Double-Blind, Placebo- and Active-Controlled, Phase 2 Study to Evaluate the Safety and Efficacy of CCX140-B in Subjects with Type 2 Diabetes Mellitus</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>NCT01028963, clinicaltrials.gov</secondaryid>
    <secondaryid>ISRCTN54010405, International Standard Randomised Controlled Trial Number Register (ISRCTN)</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Type 2 Diabetes Mellitus</healthcondition>
    <conditioncode>
      <conditioncode1>Metabolic and Endocrine</conditioncode1>
      <conditioncode2>Diabetes</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>CCX140-B capsules 5 mg once daily for 28 days (Group C); CCX140-B capsules 10 mg once daily for 28 days (Group D)</interventions>
    <comparator>Placebo (microcrystalline cellulose) capsules once daily for 28 days (Group A); 
Pioglitazone 30mg tablet once daily for 28 days (Group B)</comparator>
    <control>Active</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Subject incidence of adverse events, for example headache or fatigue, as assessed by laboratory tests, physical examinations, and subject-reported adverse events</outcome>
      <timepoint>28 days following randomization</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Effect on fasting plasma glucose concentration</outcome>
      <timepoint>28 days following randomization</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Diagnosed type 2 diabetes mellitus; must have body mass index greater than or equal to 25 and &lt;45 kg/m2, but if body mass index is greater than or equal to 25 and &lt;28, then waist circumference must be &gt;94 cm for men and &gt;80 cm for women; must be on a stable dose of metformin for at least 8 weeks prior to randomization; Hemoglobin A1c (HbA1c) of 6.5% to 10.0% inclusive and fasting plasma glucose 135 to 270 mg/dL inclusive at Screening</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>65</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Type 1 diabetes mellitus or history of diabetic ketoacidosis; received insulin treatment within 12 weeks of randomization; received chronic (more than 7 days) systemic glucocorticoid treatment within 12 weeks of randomization; received sulfonylurea, thiazolidinedione, exenatide or any other glucose lowering treatment (other than metformin) within 8 weeks of randomization; cardiac failure or history of cardiac failure (New York Heart Association [NYHA] stages I to IV), clinically evident peripheral edema, poorly controlled hypertension, history of unstable angina, syptomatic coronary artery disease, myocardial infarction or stroke within 6 months of randomization, or chronic renal failure; history or presence of drug-induced myopathy, drug-induced creatine kinase elevation, or leukopenia (white blood cell [WBC] count &lt;3.5 x 10(9)/L); history or presence of any form of cancer within the 5 years prior to randomization, with the exception of excised basal cell or squamous cell carcinoma of the skin, or cervical carcinoma in situ or breast carcinoma in situ that has been excised or resected completely and is without evidence of local recurrence or metastasis; fasting serum triglyceride &gt;400 mg/dL</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Upon determination of eligibility, randomization, stratification and allocation to treatment are done by a central  interactive voice response system (IVRS).</concealment>
    <sequence>A dynamic randomization method is used.  Eligible subjects are stratified based on monocyte chemoattractant protein-1 (MCP-1) polymorphism status and gender.</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate>29/01/2010</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>140</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Closed: follow-up continuing</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <postcode>4021</postcode>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state />
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czech Republic</country>
      <state />
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state />
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hungary</country>
      <state />
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>ChemoCentryx, Inc.</primarysponsorname>
    <primarysponsoraddress>850 Maude Avenue
Mountain View, CA 94043
USA</primarysponsoraddress>
    <primarysponsorcountry>United States of America</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>ChemoCentryx, Inc.</fundingname>
      <fundingaddress>850 Maude Avenue
Mountain View, CA 94043
USA</fundingaddress>
      <fundingcountry>United States of America</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Commercial sector/Industry</sponsortype>
      <sponsorname>Medpace, Inc.</sponsorname>
      <sponsoraddress>4620 Wesley Avenue
Cincinnati, Ohio 45212
USA</sponsoraddress>
      <sponsorcountry>United States of America</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of this study is to evaluate the safety and potential effectiveness of CCX140-B in subjects with type 2 diabetes mellitus.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Bellberry Human Research Ethics Committee</ethicname>
      <ethicaddress>Bellberry Limited
229 Greenhill Road
Dulwich  SA  5065</ethicaddress>
      <ethicapprovaldate>8/12/2009</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Multi-region Ethics Committee</ethicname>
      <ethicaddress>Ministry of Health
133 Molesworth Street
PO Box 5013
Wellington 6145</ethicaddress>
      <ethicapprovaldate>27/01/2010</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>New Zealand</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Pirow Bekker, MD, PhD</name>
      <address>ChemoCentryx, Inc.
850 Maude Avenue
Mountain View, CA 94043</address>
      <phone>+1-650-210-2900</phone>
      <fax />
      <email>pbekker@chemocentryx.com</email>
      <country>United States of America</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Dan Johnson</name>
      <address>ChemoCentryx, Inc.
850 Maude Avenue
Mountain View, CA 94043</address>
      <phone>+1-650-210-2900</phone>
      <fax />
      <email>djohnson@chemocentryx.com</email>
      <country>United States of America</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>